521 related articles for article (PubMed ID: 26314936)
1. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative.
Bendapudi PK; Li A; Hamdan A; Uhl L; Kaufman R; Stowell C; Dzik W; Makar RS
Br J Haematol; 2015 Dec; 171(5):836-44. PubMed ID: 26314936
[TBL] [Abstract][Full Text] [Related]
2. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
[TBL] [Abstract][Full Text] [Related]
3. Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score-matched study.
Li A; Makar RS; Hurwitz S; Uhl L; Kaufman RM; Stowell CP; Dzik WS; Bendapudi PK
Transfusion; 2016 Aug; 56(8):2069-77. PubMed ID: 27232383
[TBL] [Abstract][Full Text] [Related]
4. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.
Bendapudi PK; Hurwitz S; Fry A; Marques MB; Waldo SW; Li A; Sun L; Upadhyay V; Hamdan A; Brunner AM; Gansner JM; Viswanathan S; Kaufman RM; Uhl L; Stowell CP; Dzik WH; Makar RS
Lancet Haematol; 2017 Apr; 4(4):e157-e164. PubMed ID: 28259520
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant.
Mulay S; Kreuter JD; Bryant SC; Elliott MA; Hogan WJ; Winters JL; Gastineau DA
J Clin Apher; 2015 Jun; 30(3):147-53. PubMed ID: 25230249
[TBL] [Abstract][Full Text] [Related]
6. Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
Soucemarianadin M; Benhamou Y; Delmas Y; Pichereau C; Maury E; Pène F; Halimi JM; Presne C; Thouret JM; Veyradier A; Coppo P
Eur J Haematol; 2016 Aug; 97(2):183-91. PubMed ID: 26608617
[TBL] [Abstract][Full Text] [Related]
7. Indicators Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies in a Canadian Apheresis Referral Center.
Martin SD; McGinnis E; Smith TW
Am J Clin Pathol; 2021 Nov; 156(6):1103-1112. PubMed ID: 34160013
[TBL] [Abstract][Full Text] [Related]
8. Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.
Bentley MJ; Wilson AR; Rodgers GM
Vox Sang; 2013 Nov; 105(4):313-8. PubMed ID: 23662653
[TBL] [Abstract][Full Text] [Related]
9. Lombardy diagnostic and therapeutic network of thrombotic microangiopathy.
Mancini I; Agosti P; Boscarino M; Ferrari B; Artoni A; Palla R; Spreafico M; Crovetti G; Volpato E; Rossini S; Novelli C; Gattillo S; Barcella L; Salmoiraghi M; Falanga A; Peyvandi F;
Orphanet J Rare Dis; 2022 Jun; 17(1):246. PubMed ID: 35739601
[TBL] [Abstract][Full Text] [Related]
10. The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.
Bentley MJ; Lehman CM; Blaylock RC; Wilson AR; Rodgers GM
Transfusion; 2010 Aug; 50(8):1654-64. PubMed ID: 20412532
[TBL] [Abstract][Full Text] [Related]
11. Performance Validation of Three Scoring Systems for the Prediction of Thrombotic Microangiopathy Due to Severe ADAMTS13 Deficiency and the Response to Therapeutic Plasma Exchange: First Study in Korea.
Park SH; Kim HK; Jeong J; Lee SH; Lee YJ; Kim YJ; Jo JC; Lim JH
Ann Lab Med; 2023 Sep; 43(5):485-492. PubMed ID: 37080750
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange.
Clark WF
Semin Dial; 2012; 25(2):214-9. PubMed ID: 22309967
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and outcomes in patients with thrombotic microangiopathy not associated with severe ADAMTS13 deficiency.
Li A; Bendapudi PK; Uhl L; Hamdan A; Kaufman RM; Makar RS
Transfusion; 2017 Sep; 57(9):2151-2158. PubMed ID: 28635017
[TBL] [Abstract][Full Text] [Related]
15. Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura.
Connell NT; Cheves T; Sweeney JD
Transfusion; 2016 Feb; 56(2):354-9. PubMed ID: 26456149
[TBL] [Abstract][Full Text] [Related]
16. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008.
Fujimura Y; Matsumoto M
Intern Med; 2010; 49(1):7-15. PubMed ID: 20045995
[TBL] [Abstract][Full Text] [Related]
17. Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency.
Yagi H; Matsumoto M; Fujimura Y
Presse Med; 2012 Mar; 41(3 Pt 2):e137-55. PubMed ID: 22264931
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?
Shibagaki Y; Fujita T
Hypertens Res; 2005 Jan; 28(1):89-95. PubMed ID: 15969259
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic thrombocytopenic purpura--the role of ADAMTS13 assay in clinical practice.
Duraković N; Radonić R; Gasparović V
Coll Antropol; 2010 Sep; 34(3):1087-91. PubMed ID: 20977108
[TBL] [Abstract][Full Text] [Related]
20. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies.
Farkas P; Csuka D; Mikes B; Sinkovits G; Réti M; Németh E; Rácz K; Madách K; Gergely M; Demeter J; Prohászka Z
Immunobiology; 2017 Feb; 222(2):119-127. PubMed ID: 27771173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
